Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373364 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL4373361 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL8080009 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL4365322 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL4367706 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL713455 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL4370367 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL4368662 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL4369177 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 | |
| SCHEMBL4365326 | 1.00 | NPC1 (0.68) | NPC1HPGDPOLBTDP1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765984-B2 | Methods and systems for making thiol compounds from terminal olefinic compounds | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232297-A1 | Methods and Systems for Making Thiol Compounds from Terminal Olefinic Compounds | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2009132010-A1 | METHODS AND SYSTEMS FOR MAKING THIOL COMPOUNDS FROM TERMINAL OLEFINIC COMPOUNDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264669-A1 | Methods and Systems for Making Thiol Compounds from Terminal Olefinic Compounds | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2009-10-22 | — | — | US | disclosed |
| CN-1444494-A | Method for utilizing scanning probe microscope tip and product thereof or manufacturing method of product | UNIV NORTHWESTERN (US) | 2003-09-24 | — | — | CN | disclosed |
| US-4178301-A | 4-(2-(ACETYLTHIO)ACETAMIDO)BENZOIC ACID AS MUCOLYTIC AGENT | MEAD JOHNSON & COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
| US-4132802-A | LIQUEFACTION OF MUCUS | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
| US-4096277-A | Mucolytic mercaptoacylamidobenzamides and process of using same | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4005222-A | Mucolytic mercaptoacylamidobenzoic and benzenesulfonic acid compounds and process | MEAD JOHNSON & COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232297-A1 | Methods and Systems for Making Thiol Compounds from Terminal Olefinic Compounds | TST, HHAT, GSTO1 | NPC1 1210/4885HPGD 124/4885POLB 3543/4885 |
| US-20090264669-A1 | Methods and Systems for Making Thiol Compounds from Terminal Olefinic Compounds | TST, HHAT, GSTO1 | NPC1 1210/4885HPGD 124/4885POLB 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.